HCP|NETWORK.
Sign In
Please enter a keyword or adjust filters to filter the search.
Planetary Health
15th Jan, 2026
The Lancet
Temperature variability disrupts health-care delivery, straining service capacity during busy periods. These findings provide the first system-wide benchmark for understanding the health burden of temperature, highlighting potential discrepancies between mortality and access to care. Globally, health-care systems must anticipate these disruptions, and adaptation policies outside of health-care systems are essential to reduce health and financial pressures. Investments in climate-resilient infrastructure and strategies to protect vulnerable populations, especially older adults, are urgently needed.
Heat stress significantly reduces the physical effort during labour. Self-employed subsistence farmers appear to adapt to heat stress by lowering labour intensity, redistributing tasks throughout the day, and shifting work to cooler months. As climate change worsens, these adaptations could become inadequate. Women, who often balance household chores and fieldwork, have limited pacing strategies, heightening their vulnerability to increasing heat stress. Our findings highlight the urgent need for targeted adaptation strategies to sustain physical effort during labour and protect vulnerable groups, especially women, from escalating heat stress.
In November, 2025, government and experts will meet in Brazil for the 30th meeting of the Conference of the Parties to the United Nations Framework Convention on Climate Change (COP30). In preparation, WHO and the Brazilian Government jointly convened the Fifth Global Conference on Climate and Health in July, 2025. The resulting Belém Health Action Plan for the Adaptation of the Health Sector to Climate Change is multifaceted and includes core climate–health targets: equity, justice, and capacity building.
The past decade was officially the hottest on record,1 highlighting humanity's failure to curb greenhouse gas emissions and the urgent need for decisive climate action. The scientific community and civil society demand prioritising human health in this agenda, supported by evidence on greater societal engagement and by the archetype of reliability, ethics, and responsibility embodied by health professionals.2,3 Although there is a growing awareness among health professionals and health institutions regarding the causal relationship between climate change and disease, this sector still lacks political will, funding, and infrastructure to lead ambitious and equitable response policies.
Climate change is threatening the health and wellbeing of billions.1 To avert most severe risks of climate change and ensure a safe and liveable planet, global warming must be constrained as much as possible. The core aim of the Paris Agreement is to limit global average temperature increase to ‘well below 2oC’ and pursue efforts to limit warming to 1·5oC above pre-industrial levels.2 The UN, many international agencies, non-government organisations, and climate action groups have focused on achieving this goal (figure).
In 1995, health ministers from the Pacific Islands gathered on Yanuca Island, Fiji, to declare a visionary Healthy Islands idea, a holistic framework linking human wellbeing with environmental stewardship. The ministers imagined island communities where children thrive, people live and age with dignity, and “ecological balance is a source of pride and the ocean which sustains us is protected”.1 This Healthy Islands vision anticipated by decades the core principles of the current planetary health movement.
Over the past 15 years, there has been an increasing commitment to educate and develop the health workforce on the impacts of climate change, integrating key competencies related to climate into medical education and training.1–3 Modifications in medical training include the introduction of new core competencies such as climate change into global health curriculum.4
Since 2007, outbreaks of chikungunya and dengue have become increasingly frequent and large scale in Europe. The frequency and size of these episodes suggest a concerning trend. In 2025 alone, there have been an unprecedented 81 locally acquired chikungunya outbreaks, with a total of 1124 cases to date.1 Another particularly concerning event occurred in October, 2024, when Italy had the largest recorded dengue outbreak in Europe, with more than 200 confirmed autochthonous cases.2 Although this number might seem small compared to outbreaks in endemic regions such as southeast Asia or Latin America, in the European context, it represents an unprecedented scale with epidemic potential.
It is customary at the end of each year for The Lancet Planetary Health editorial to summarise global environmental change progress and developments. But as 2025 draws to a close, it seems that we could, with minimal editing, simply copy and paste editorial summaries from previous years. That is a facetious statement; of course, there have been positive developments, grinding progress, and wins on some key issues, for example the acceleration in green electricity capacity, the inclusion of health in key climate negotiations, and success in climate change litigation.
Rheumatology
31st Dec, 2025
Journal of the American Medical Association
A patient receiving adalimumab for rheumatoid arthritis had ulcerated plaques on the anterior and lateral aspects of the neck, upper chest, and nape and erythroderma on the dorsum of the hands, corresponding to areas of sun exposure, as well as swelling of the proximal interphalangeal hand joints bilaterally. What is the diagnosis and what would you do next?
Medical News
23rd Dec, 2025
phys.org
Maryland officials have confirmed a second positive test for bird flu at a commercial poultry operation in Queen Anne's County, the 10th detection in the state in 2025, as public health experts warn the virus continues to pose a serious threat to animals—but remains a low risk for most people.
What's New: Vaccines, Blood and Biologics
FDA
Center for Biologics Evaluation and Research
STN# 125317 Proper Name: Fibrinogen Concentrate (Human) Tradename: RIASTAP Manufacturer: CSL Behring GmbH Indication: Treatment of of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Product Information Package insert - RIASTAP Supporting Documents December 19, 2025 Approval Letter - RIASTAP Statistical Review - RIASTAP Clinical Review Memorandum - RIASTAP June 4, 2021 Approval Letter - RIASTAP January 16, 2009 Approval Letter - RIASTAP Summary Basis for Regulatory Action - RIASTAP (125317/0) Approval History, Letters, Reviews and Related Documents - RIASTAP
The.gov means it’s official. Federal government websites often end in.gov or.mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
What's New: Drugs
7th Apr, 2026
Center,
Research
8th Apr, 2026
PNAS Podcast
Medical Journal
Diabetes Journals
6th Apr, 2026
